SCHEMBL2176945

SCHEMBL2176945

c1ccc(N2CC[N]C(N3CCC3)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MBTD1 Q05BQ5 1/20 0.45
NOTUM Q6P988 1/20 0.39
LMNA P02545 2/20 0.39
SLC18A3 Q16572 1/20 0.37
BPTF Q12830 1/20 0.36
MAPT P10636 1/20 0.36
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
ADRB1 P08588 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
GRIN2B Q13224 1/20 0.35
AKR1C3 P42330 1/20 0.35
KDM4E B2RXH2 1/20 0.34
TSHR P16473 1/20 0.34
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9046550 0.80 SLC2A1 (0.40) L3MBTL1LMNASLC18A3MAPTGRIN2B
SCHEMBL8103990 0.80 ALDH1A1 (0.41) L3MBTL3L3MBTL1NOTUMLMNAHTR3E
SCHEMBL11555679 0.76 GRIN2B (0.42) L3MBTL3L3MBTL1MBTD1LMNASLC18A3
SCHEMBL8105737 0.74 PLD1 (0.43) LMNAMAPTGRIN2BKDM4EDRD2
SCHEMBL6526654 0.74 NOTUM (0.42) L3MBTL3L3MBTL1MBTD1NOTUMLMNA
SCHEMBL2094438 0.72 MAPK1 (0.45) L3MBTL3L3MBTL1MBTD1NOTUMLMNA
SCHEMBL4636682 0.72 SLC18A3 (0.54) L3MBTL3L3MBTL1MBTD1LMNASLC18A3
SCHEMBL26417406 0.71 L3MBTL3 (0.63) L3MBTL3L3MBTL1MBTD1NOTUMLMNA
SCHEMBL6344083 0.70 SMN1; SMN2 (0.50) SLC18A3MAPTADRB1KDM4ETSHR
SCHEMBL4468038 0.70 NOTUM (0.39) L3MBTL3L3MBTL1MBTD1NOTUMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 US disclosed
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases LNCYTE CORPORATION (US) 2008-07-10 US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 L3MBTL3 3622/4885L3MBTL1 3147/4885MBTD1 2756/4885
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases MMP25, MMP9, MMP24 L3MBTL3 2998/4885L3MBTL1 2118/4885MBTD1 3258/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 L3MBTL3 3905/4885L3MBTL1 3117/4885MBTD1 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.